Achim J Kaasch,Luis Eduardo López-Cortés,Jesús Rodríguez-Baño,José Miguel Cisneros,M Dolores Navarro,Gerd Fätkenheuer,Norma Jung,Siegbert Rieg,Raphaël Lepeule,Laetitia Coutte,Louis Bernard,Adrien Lemaignen,Katrin Kösters,Colin R MacKenzie,Alex Soriano,Stefan Hagel,Bruno Fantin,Matthieu Lafaurie,Jean-Philippe Talarmin,Aurélien Dinh,Thomas Guimard,David Boutoille,Tobias Welte,Stefan Reuter,Jan Kluytmans,Maria Luisa Martin,Emmanuel Forestier,Hartmut Stocker,Virginie Vitrat,Pierre Tattevin,Anna Rommerskirchen,Marion Noret,Anne Adams,Winfried V Kern,Martin Hellmich,Harald Seifert,Adoración Valiente,Marina de Cueto,Ángel Rodríguez,José Molina,Julia Fischer,Gregor Paul,Sébastien Gallien,Vincent Fihman,Marion Lacasse,Francois Coustillères,Christian Becker,André Fuchs,Laura Morata,Sebastian Weis,Diane Ponscarme,Lydie Khatchatourian,Elisabeth Rouveix,Dominique Merrien,Raphaël Lecomte,Jacobien Veenemans,Helem H. Vilchez,Johanna Kessel,Marc J.M. Bonten,Jan Rupp,Laurent Hocqueloux,Frederic Lucht,Jean-Paul Stahl,Anne Vlek,Reinhild Prinz-Langenohl,Violaine Tolsma

Abstract:Summary Background Staphylococcus aureus bloodstream infection is treated with at least 14 days of intravenous antimicrobials. We assessed the efficacy and safety of an early switch to oral therapy in patients at low risk for complications related to S aureus bloodstream infection. Methods In this international, open-label, randomised, controlled, non-inferiority trial done in 31 tertiary care hospitals in Germany, France, the Netherlands, and Spain, adult patients with low-risk S aureus bloodstream infection were randomly assigned after 5–7 days of intravenous antimicrobial therapy to oral antimicrobial therapy or to continue intravenous standard therapy. Randomisation was done via a central web-based system, using permuted blocks of varying length, and stratified by study centre. The main exclusion criteria were signs and symptoms of complicated S aureus bloodstream infection, non-removable foreign devices, and severe comorbidity. The composite primary endpoint was the occurrence of any complication related to S aureus bloodstream infection (relapsing S aureus bloodstream infection, deep-seated infection, and mortality attributable to infection) within 90 days, assessed in the intention-to-treat population by clinical assessors who were masked to treatment assignment. Adverse events were assessed in all participants who received at least one dose of study medication (safety population). Due to slow recruitment, the scientific advisory committee decided on Jan 15, 2018, to stop the trial after 215 participants were randomly assigned (planned sample size was 430 participants) and to convert the planned interim analysis into the final analysis. The decision was taken without knowledge of outcome data, at a time when 126 participants were enrolled. The new sample size accommodated a non-inferiority margin of 10%; to claim non-inferiority, the upper bound of the 95% CI for the treatment difference (stratified by centre) had to be below 10 percentage points. The trial is closed to recruitment and is registered with ClinicalTrials.gov ( NCT01792804 ), the German Clinical trials register (DRKS00004741), and EudraCT (2013–000577–77). Findings Of 5063 patients with S aureus bloodstream infection assessed for eligibility, 213 were randomly assigned to switch to oral therapy (n=108) or to continue intravenous therapy (n=105). Mean age was 63·5 (SD 17·2) years and 148 (69%) participants were male and 65 (31%) were female. In the oral switch group, 14 (13%) participants met the primary endpoint versus 13 (12%) in the intravenous group, with a treatment difference of 0·7 percentage points (95% CI –7·8 to 9·1; p=0·013). In the oral switch group, 36 (34%) of 107 participants in the safety population had at least one serious adverse event compared with 27 (26%) of 103 participants in the intravenous group (p=0·29). Interpretation Oral switch antimicrobial therapy was non-inferior to intravenous standard therapy in participants with low-risk S aureus bloodstream infection. However, it is necessary to carefully assess patients for signs and symptoms of complicated S aureus bloodstream infection at the time of presentation and thereafter before considering early oral switch therapy. Funding Deutsche Forschungsgemeinschaft. Translations For the German, Spanish, French and Dutch translations of the abstract see Supplementary Materials section.

Does adjunctive clindamycin have a role in Staphylococcus aureus bacteremia? A protocol for the adjunctive treatment domain of the S. aureus Network Adaptive Platform (SNAP) randomized controlled trial

Adjunctive linezolid versus clindamycin for toxin inhibition in β-lactam-treated patients with invasive group A streptococcal infections in 195 US hospitals from 2016 to 2021: a retrospective cohort study with target trial emulation

Daptomycin versus placebo as an adjunct to beta-lactam therapy in the treatment of Staphylococcus aureus bacteremia: study protocol for a randomized controlled trial

Early oral antibiotic switch in Staphylococcus aureus bacteraemia: The Staphylococcus aureus Network Adaptive Platform (SNAP) Trial Early Oral Switch Protocol

The Staphylococcus aureus Network Adaptive Platform Trial Protocol: New Tools for an Old Foe

Clinical sub-phenotypes of Staphylococcus aureus bacteraemia

Ways to Improve Insights into Clindamycin Pharmacology and Pharmacokinetics Tailored to Practice

Adjuvant Beta-Lactam Therapy Combined With Vancomycin Or Daptomycin For Methicillin-Resistant Staphylococcus Aureus Bacteremia: A Systematic Review And Meta-Analysis

Targeting Alpha Toxin and ClfA with a Multimechanistic Monoclonal-Antibody-Based Approach for Prophylaxis of Serious Staphylococcus aureus Disease

Therapeutic efficacy of clindamycin gel as an adjunct to scaling and root planing therapy in chronic periodontal disease

Prognostic factors for streptococcal toxic shock syndrome: systematic review and meta-analysis

1818. A Network Meta-Analysis of Antibiotic Efficacy for the Treatment of Skin and Soft Tissue Infections

Comparative in vitro efficacy of antibiotics against the intracellular reservoir of Staphylococcus aureus

Clarithromycin, as an adjunct to non surgical periodontal therapy for chronic periodontitis: a double blinded, placebo controlled, randomized clinical trial

Efficacy and safety of an early oral switch in low-risk Staphylococcus aureus bloodstream infection (SABATO): an international, open-label, parallel-group, randomised, controlled, non-inferiority trial

Rapid de-escalation of anti-MRSA therapy guided by S. aureus nares screening for patients with pneumonia: protocol of a randomized controlled trial (SNAP study)

Scientific Rationale and Clinical Basis for Clindamycin Use in the Treatment of Dermatologic Disease

Anti-virulence potential of iclaprim, a novel folic acid synthesis inhibitor, against Staphylococcus aureus

Toxin inhibition: Examining tetracyclines, clindamycin, and linezolid

Genomic investigation and clinical correlates of the in vitro β-lactam: NaHCO3 responsiveness phenotype among methicillin-resistant Staphylococcus aureus isolates from a randomized clinical trial

Exploring combination treatment options for persistent methicillin-susceptible Staphylococcus aureus bacteremia